

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CLARIFICATION ANNOUNCEMENT IN RELATION TO PROPOSED SHARE CONSOLIDATION AND CHANGE IN BOARD LOT SIZE

Reference is made to the announcement of China NT Pharma Group Company Limited (the “**Company**”) dated 14 May 2024 in relation to the proposed share consolidation and change in board lot size (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

The Company wishes to clarify the section headed “**Proposed share consolidation**” and “**Effects of the proposed Share Consolidation**” on page 1 to 3.

“The Board proposes to implement the Share Consolidation on the basis that every ten (10) issued and unissued Existing Shares and Existing Convertible Preference Shares (“**Existing CPSs**”) of par value of US\$0.00000008 each be respectively consolidated into one (1) Consolidated Share and one (1) Consolidated CPS of par value of US\$0.00000008 each.

As at the date of this announcement, the authorised share capital of the Company is US\$50,100 divided into 625,925,000,000 Existing Shares and 325,000,000 Existing CPSs.

Upon the Share Consolidation becoming effective and assuming that there are no changes on the authorised share capital of the Company from the date of this announcement until the effective date of the Share Consolidation, the authorised share capital of the Company will become US\$50,100 divided into 62,592,500,000 Consolidated Shares with par value of US\$0.00000008 each and 32,500,000 Consolidated CPSs with par value of US\$0.00000008 each.

As at the date of this announcement, 2,640,895,063 Existing Shares have been issued and no Existing CPS is in issue. Upon the Share Consolidation becoming effective and assuming that no new Existing Shares and/or new Existing CPSs are issued nor Existing Shares are repurchased from the date hereof until the effective date of the Share Consolidation, 264,089,506 Consolidated Shares and no Consolidated CPS will be in issue.”

Also, the Company wishes to clarify the section headed “**Adjustment in relation to the other securities of the Company**” on page 5.

“As at the date of this announcement, the Company has outstanding Share Options entitling the holders thereof to subscribe for a total of 20,200,000 Existing Share”.

Save as disclosed above, all other information in the Announcement remains unchanged.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 5 June 2024

As at the date of this announcement, the Board comprises the following Directors:

Executive Directors

Mr. Ng Tit (*Chairman*)

Ms. Ng, Anna Ching Mei

Non-executive Directors

Dr. Qian Wei

Ms. Chin Yu

*Independent Non-executive
Directors*

Mr. Yu Tze Shan Hailson

Mr. Ng Ming Kwan

Dr. Zhao Yubiao